Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1557746/000155837018004349/acrs-20180331x10q.htm
January 2023
January 2023
December 2022
November 2022
November 2022
August 2022
August 2022
June 2022
May 2022
April 2022
Exhibit 99.1
Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
· |
Management to Host Conference Call at 5:00 PM ET today |
Wayne, PA – May 8, 2018 (GLOBE NEWSWIRE) – Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology, and immunology, today announced financial results for the first quarter 2018 and provided an update on its clinical development and commercial programs.
“The first quarter of 2018 was a busy one as we prepared for the launch of ESKATA™ (hydrogen peroxide) Topical Solution, 40% (w/w), the first and only FDA-approved topical treatment for raised seborrheic keratosis (SK). We held the ESKATA Launch Meeting last week, and ESKATA is now officially available for physicians and their patients,” said Brett Fair, Chief Commercial Officer of Aclaris.
Commercial Update:
· |
Successful rollout and implementation of the ESKATA Early Experience Initiative (EEI). |
o |
Program expanded to over 700 accounts to accommodate market demand for ESKATA. |
o |
Ongoing in-service programs to support successful training and product integration. |
o |
Positive initial ESKATA feedback from EEI program captured in physician and patient post-application surveys. |
· |
Aclaris sales force successful in generating a significant number of ESKATA pre-orders from targeted accounts ahead of official launch meeting. |
o |
Commenced health care provider (HCP) order processing and shipping the week of April 23, 2018. |
· |
ESKATA Launch Campaign Highlights: |
o |
ESKATA Launch Meeting held April 30 – May 4, 2018; Unveiled New ESKATA Campaign; sales force trained on new tools and resources to support a successful ESKATA launch. |
o |
ESKATA Consumer website (www.eskata.com) launched May 1, 2018; includes “Find A Doctor” resource for patients seeking ESKATA treatment. |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1557746/000155837018004349/acrs-20180331x10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aclaris Therapeutics, Inc..
Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Aclaris Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ACRS
CIK: 1557746
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-18-004349
Submitted to the SEC: Tue May 08 2018 5:15:48 PM EST
Accepted by the SEC: Tue May 08 2018
Period: Saturday, March 31, 2018
Industry: Pharmaceutical Preparations